(Reuters Health)—Doctors who receive payments or gifts from pharmaceutical companies are more likely to prescribe brand name medications, a new study suggests. Dr. James Yeh, of Brigham and Women’s Hospital in Boston, and colleagues write May 9 online in JAMA Internal Medicine that some states require doctors to report what they receive from drug companies….
Articles by Natasha Yetman
U.K. Cost Body Finally Approves Limited Use of GSK’s Lupus Drug
LONDON (Reuters)—Britain’s healthcare cost watchdog has finally approved GlaxoSmithKline’s lupus drug Benlysta (belimumab) for limited use, after rejecting it since 2011 on the grounds that it failed to offer good value for money. The National Institute for Health and Care Excellence (NICE) said on Tuesday that the drug would be made available under a managed…
U.S. Probes Contracts Between Drugmakers, Pharmacy Benefit Managers
(Reuters)—The U.S. Attorney’s Office for the Southern District of New York is investigating contracts between drugmakers and companies that manage prescription benefits, according to regulatory filings. Federal prosecutors have approached at least three companies, including Johnson & Johnson, Merck & Co. and Endo International Plc., demanding information about their contracts with pharmacy benefit managers. Pharmacy…
Inefficient Prescribing Costs Billions of Healthcare Dollars
(Reuters Health)—In the U.S. between 2010 and 2012, nearly $73 billion was spent on brand name medications instead of less expensive alternatives, according to a new study. A large portion of that money was spent by patients, the researchers found. “Prescription drug prescribing during the time of this paper was not efficient and still isn’t…
Medicare Telemedicine Underuse May Not Be Due to Reimbursement Policies
NEW YORK (Reuters Health)—Contrary to previous research, mandating commercial insurance reimbursement of telemedicine was not associated with faster growth in Medicare telemedicine use, according to a newly published study. Dr. Ateev Mehrotra of Harvard Medical School, Boston, and colleagues examined trends in telemedicine utilization by Medicare from 2004–2013 using claims from a 20% random sample…
Golimumab Effective as Maintenance Treatment for Active Ulcerative Colitis
NEW YORK (Reuters Health)—Subcutaneous golimumab every four weeks provides effective long-term maintenance for patients with active ulcerative colitis (UC), according to results from the PURSUIT-SC extension study. The main PURSUIT-M study showed that golimumab treatment maintained clinical responses through Week 54. For most patients, maintenance therapy for UC is required long term. Dr. Peter R….
Antibodies Can Spot RA in the General Population
NEW YORK (Reuters Health)—Anti-citrullinated protein antibodies (ACPA), particularly high anti-CCP2 titers, can diagnose rheumatoid arthritis (RA) in the general population with a high degree of accuracy, a Swedish study suggests. ACPA are highly specific for RA, but until now the diagnostic accuracy of ACPA in the general population has not been “thoroughly assessed,” note Dr….
Foot Orthoses vs. Rocker-Sole Footwear: Which Treatment Is More Effective for Reducing Pain in First MPT Joint OA?
Foot osteoarthritis (OA) of the first metatarsophalangeal (MTP) joint is thought to have biomechanical factors, but its treatments have not been comprehensively tested in clinical trials. In the first study to explore the efficacy of mechanical interventions, researchers compared the effectiveness of foot orthoses and rocker-sole footwear in reducing pain. Both interventions were effective, but the foot orthoses group wore the intervention for significantly more hours than the footwear group…
Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis
NEW YORK (Reuters Health)—About two-thirds of patients with ulcerative colitis (UC) had mucosal healing by the end of induction treatment with the infliximab biosimilar CT-P13, according to results of the first prospective study to evaluate this. CT-P13 is the first biosimilar monoclonal antibody of reference infliximab (Remicade) approved in Europe and several other countries where…
Regeneron Pain Drug Clears Late-Stage Trial
(Reuters)—Drugmaker Regeneron Pharmaceuticals Inc. said on Monday its experimental drug to treat moderate to severe osteoarthritis pain was successful in a late-stage study. The drug, fasinumab, was tested on 421 patients with a history of inadequate pain relief or intolerance to current painkillers. Fasinumab binds to nerve growth factor (NGF) proteins and block their activity,…
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 98
- Next Page »